https://www.selleckchem.com/products/bi-1347.html
8,p=0.39). No evidence for a difference in the risk of disability progression was observed. In treated patients with SPMS, high-efficacy therapy is superior to low-efficacy therapy in reducing relapses in patients with active, but not those with inactive, SPMS. However, more potent therapies do not offer an advantage in reducing disability progression in this patient group. This study provides class III evidence that high-efficacy therapy is superior to low-efficacy therapy in reducing relapses in patients with active SPMS whilst we did
Like
Comment
Share
